Swiss banks are in the center of news attention at the beginning of a new week. UBS agreed to buy Credit Suisse in a government-brokered deal aimed at restoring calm and confidence in the European banking sector. UBS will purchase Credit Suisse for 3 billion CHF and receive additional 9 billion CHF in government guarantees. On top of that, additional liquidity to a combined entity will also be provided. Government guarantees to UBS should not come as a surprise given that the bank will also assume around 5 billion CHF in Credit Suisse losses.
UBS takeover of Credit Suisse leads to an interesting and potentially dangerous situation in the Swiss banking sector. Tie-up of two largest Swiss banks means that over 50% of bank deposits in the country will be held by a single institution! This is a massive concentration and could have grave consequences for Swiss banking sector stability should UBS encounter a bank run. However, UBS is not Credit Suisse and has a much better record of not getting involved in market scandals and other suspicious activities. Not to mention that Swiss regulators are likely to pay double attention not to let this behemoth fail. On the other hand, it means that once current turmoil is over, discussions about splitting up UBS may commence.
In spite of being two largest banks in Switzerland, Credit Suisse and UBS had a less than 10% combined share in SMI (SUI20) - index of 20 largest Swiss stocks. This index is dropping slightly over 1% today and is one of Europe's top laggards. Taking a look at SUI20 chart at weekly interval (W1), we can see that the index launched a new week with a bearish price gap and tested the 10,300 pts support zone. Bulls managed to defend the area on the first attempt and now attempt to launch a recovery move.
Source: xStation5
Daily Summary: US2000 leads on Wall Street📈Crypto and metals up, US dollar down
3 markets to watch next week (03.10.2025)
US500 hits new all-time high📈Applied Materials loses, RareEarth USA surges on US deal rumors
DE40: Europe looking for direction amid mixed PMI reports
The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.
